PEG-MGF: Purpose of the Polymer, Its Costs and Certificate Checks

Take mechano growth factor — the E-domain peptide of 24 residues found at the far end of the IGF-1 Ec splice product — and bond a polyethylene glycol chain to it, and you have PEG-MGF. Nothing in the peptide sequence is altered. The polymer is there for handling and pharmacokinetics alone. Published reports give unmodified MGF a lifetime of only minutes, whether in buffer or in serum, so experiments that require more than brief local presence are very hard to arrange. Conjugation lengthens that period considerably; that alone is why the modified form is made.

We offer PEG-MGF freeze-dried in 2 mg and 5 mg vials, listed with the IGF and muscle peptides and sold for laboratory research only.

Defining PEG-MGF

The molecule has two parts. Its peptide core is the sequence also sold as plain MGF: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys, the distinctive C-terminal region that appears when the IGF-1 gene is spliced into the Ec form muscle raises after mechanical loading. The other part is a polyethylene glycol polymer joined to a reactive site on the peptide, typically the N-terminal amine or a lysine side chain.

PEG is not one substance but a distribution of chain lengths, so no single CAS registry number or molecular mass applies to this conjugate. How heavy a given batch is depends on which PEG chain was used, and for that reason the mass figure belongs to the individual lot's paperwork rather than to a catalogue entry. Expect this of any conjugate; it is not an omission.

The chemistry and its trade-off

PEGylation is a long-established technique in protein chemistry, used well before anyone applied it to MGF; the same approach underlies licensed biologics such as pegfilgrastim and peginterferon. Attaching a water-loving polymer increases the effective size of the molecule, which reduces how readily the kidney filters it, and it physically masks the backbone from proteases and from receptor or antibody contact.

That protection comes at a price inherent to the method: the same shield that keeps enzymes away also keeps the peptide less accessible, so conjugates generally show lower activity per molecule in vitro while doing better wherever duration matters. This pattern recurs across the PEGylated-biologic literature and should be the working assumption for PEG-MGF unless a given study shows something else.

The other structural issue is heterogeneity. Unless the coupling chemistry is strictly site-specific, the preparation contains a family of species — mono- and di-PEGylated forms plus positional isomers — rather than a single compound. That has direct implications for how the analytical certificate should be read.

Proposed mechanism

Any biological activity resides in the peptide core, and the main caveat carries over unchanged: no receptor for the MGF E-domain has been identified. Cell studies report that the E-domain promotes myoblast proliferation while delaying fusion into myotubes — the opposite of mature IGF-1, which pushes cells towards differentiation. That opposition is the main reason to think the E-domain acts by a mechanism of its own rather than as a weak IGF-1R agonist. Proposed routes include charge-driven interaction with the membrane and nuclear localisation observed in some cell work; none is established.

Signalling is untouched by conjugation — only the exposure curve moves. So the conjugate belongs in studies that want peptide present at a steadier level over a longer stretch, while the unmodified peptide belongs in studies built around a brief, well-delimited pulse: think of asking at what moment satellite cells switch on, as opposed to how many do. In other words, duration is the variable you are choosing, and our MGF vs PEG-MGF comparison talks that decision through.

Research to date

Myoblast and satellite cell work

Cell work with the E-domain peptide, conjugated or not, has focused on markers of proliferation, delayed myotube fusion and satellite-cell activation in C2C12 and primary cultures. These are in-vitro measurements.

Injury and regeneration models

In rodents, E-domain peptide has been administered in crush, cardiotoxin and eccentric-damage muscle models, with reported changes in regeneration markers and fibre cross-sectional area. The studies are small and have not been replicated at scale, so this is exploratory preclinical work.

Pharmacokinetics and formulation

The body of literature most directly relevant to PEG-MGF has nothing to do with muscle at all: it is the general PEGylation literature on clearance, immunogenicity and the activity trade-off, which is mature and consistently reproduced. Our guide to peptide stability and half-life explains why modifications such as DAC, PEG and acetylation exist and what each one buys.

Expression studies on IGF-1 Ec

The most solid evidence linking this splice variant to mechanical load comes from transcript measurements in loaded muscle, in rodents and in human biopsies. Those data are what generated interest in the peptide, but they say nothing about the effect of administering it.

Formats and sizes

One warning before you calculate molarity. On a conjugate, a label reading 5 mg refers to conjugate, not to peptide. Polymer makes up some of that mass, so there is less peptide in the vial than the number suggests, and the size of the shortfall varies with chain length. When two arms of a study must be matched mole for mole — one conjugated, one not — base the calculation on the certificate's peptide content. Purchasing considerations appear in our PEG-MGF buying guide.

Reconstitution and storage in the lab

Conjugation makes aqueous handling simpler, and PEG-MGF goes into bacteriostatic or sterile water easily. Let the solvent run down the glass onto the cake and swirl gently: conjugates foam readily, and foam is an obstacle to withdrawing an accurate volume rather than a sign that anything is wrong with the peptide.

Bench arithmetic, not a protocol: 5 mg in 2 mL of diluent gives 2.5 mg/mL of conjugate (2,500 mcg/mL), so 0.1 mL — the 10-unit line on a U-100 syringe — holds 250 mcg of conjugate. Turning that figure into peptide-equivalent terms needs the certificate value mentioned above. The general procedure is in our reconstitution guide.

Store unopened freeze-dried vials sealed at −20 °C, dry and dark. Reconstituted material lasts for short-term work at 2-8 °C; longer studies should work from frozen aliquots rather than thawing and refreezing one stock. General practice is covered in how to store peptides.

Purity and reading the COA

Reading a conjugate certificate calls for different priorities than a plain peptide one. Three items carry the most weight. Number one is how many PEG chains are attached and how heavy they are (the polymer molecular weight); lacking those two numbers, you cannot convert the vial's contents into moles. Number two is which species are present: material that is uniformly singly conjugated is not the same reagent as a mixture of singly and doubly conjugated forms, and either HPLC or a gel should tell you. Number three is residual unconjugated peptide, which behaves unlike the conjugate in any assay.

The purity percentage by peak area retains some value, but it decides less than usual, since a wide spread of chain lengths broadens the peak even when nothing impure is present. For how the chromatography and mass spectrometry sections relate to each other, see our page on interpreting a peptide certificate.

Regulatory position

PEG-MGF is not authorised as a medicine in any country, has no reference-listed product and no approved label, and no approved use in any form. In sport, IGF-1 and its splice-variant peptides fall under the anti-doping prohibitions on growth factors.

Related compounds and further reading

Plain MGF is the parent molecule. Two relatives do activate the receptor — IGF-1 LR3 and IGF-1 DES (1-3) — but because they signal through IGF-1R they answer a quite separate question from anything in the E-domain family.

Matching catalogue section: IGF & Muscle Peptides